TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16091265

Group type: EXPERIMENTAL
Intervention: Explicit condition with semantically studied words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit condition with deep encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit task with awareness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control words in implicit task
Number of subjects: 0
Study: 12131114

Group type: EXPERIMENTAL
Intervention: PMP-membrane oxygenators
Number of subjects: 24

Group type: COMPARATOR
Intervention: PPL-membrane oxygenators
Number of subjects: 24
Study: 9924160

Group type: EXPERIMENTAL
Intervention: c7E3 (abciximab)
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Control (no abciximab)
Number of subjects: 2099
Study: 7762533

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) for 6 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: healthy control subjects
Number of subjects: 12
Study: 2271205

Group type: EXPERIMENTAL
Intervention: 0.3 micrograms/kg of prostaglandin E1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.6 micrograms/kg of prostaglandin E1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study: 7397293

Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31775403

Group type: EXPERIMENTAL
Intervention: Parasagittal interlaminar (PIL) approach
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Transforaminal (TF) approach
Number of subjects: 65

Group type: COMPARATOR
Intervention: Midline interlaminar (MIL) approach
Number of subjects: 65
Study: 29931459

Group type: EXPERIMENTAL
Intervention: Vitamin D3, 70 µg (2800 IU)/day for three months
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 27368021

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation at 62°C
Number of subjects: 1354

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation at 65°C
Number of subjects: 1354

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation at 68°C
Number of subjects: 1354

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation at 62°C, 65°C, and 68°C
Number of subjects: 1354
Study: 24439641

Group type: EXPERIMENTAL
Intervention: Body acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenglong method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22521904

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 67
Study: 19923079

Group type: EXPERIMENTAL
Intervention: Coopdech endobronchial blocker tube (BB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Double-lumen endobronchial tube (DLT)
Number of subjects: 36
Study: 17846932

Group type: EXPERIMENTAL
Intervention: Insulin only (IO)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Bedtime insulin with sulphonylurea (IS)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Bedtime insulin with metformin (IM)
Number of subjects: 52
Study: 15353978

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No Mycophenolate mofetil (Control)
Number of subjects: 19
Study: 12187213

Group type: EXPERIMENTAL
Intervention: Single 500 mg oral dose of levofloxacin
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Additional doses of levofloxacin for high-risk patients
Number of subjects: 400
Study: 10542974

Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate (FP) 2000 micrograms daily via Diskhaler
Number of subjects: 395

Group type: COMPARATOR
Intervention: Budesonide (BUD) 2000 micrograms daily via Turbuhaler
Number of subjects: 395
Study: 7606904

Group type: EXPERIMENTAL
Intervention: Feedback and reasoning explanation during training sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Feedback alone during training sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Feedback with no reasoning explanation during training sessions
Number of subjects: 0
Study: 2132162

Group type: EXPERIMENTAL
Intervention: Dihydroxyacetone (DHP)
Number of subjects: 7
Study: 112550

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31813273

Group type: EXPERIMENTAL
Intervention: PTCAP program (8 hr of training in practice guidelines and brief therapeutic skills for depression, anxiety, ADHD, and behavioral disorders)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (practiced as usual)
Number of subjects: 76
Study: 31585489

Group type: EXPERIMENTAL
Intervention: Ceramide-containing moisturizer
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hydrophilic cream
Number of subjects: 24
Study: 28371223

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump therapy
Number of subjects: 32
Study: 25968058

Group type: EXPERIMENTAL
Intervention: Blind subjects (congenital and acquired)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sighted controls
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Congenital blindness
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Acquired blindness
Number of subjects: 66
Study: 23351277

Group type: EXPERIMENTAL
Intervention: Acetaminophen elixir (10-15 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acetaminophen suppository (10-15 mg/kg)
Number of subjects: 30
Study: 21069379

Group type: EXPERIMENTAL
Intervention: 100% oxygen for 45 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Medical air for 45 min
Number of subjects: 10
Study: 19477353

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin daily for 12 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: 10 mg atorvastatin daily for 12 weeks
Number of subjects: 47
Study: 16451147

Group type: EXPERIMENTAL
Intervention: 80% oxygen in nitrogen and saline 2 ml intravenously (i.v.) at the end of surgery (group 80)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 30% oxygen in nitrogen and saline 2 ml intravenously (i.v.) at the end of surgery (group 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 30% oxygen in nitrogen and ondansetron 4 mg (group O)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 80% oxygen in nitrogen and saline 2 ml intravenously (i.v.) (group 80)
Number of subjects: 90
Study: 15648986

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tenoxicam
Number of subjects: 35
Study: 15225176

Group type: EXPERIMENTAL
Intervention: 3-day rabeprazole-based treatment (rabeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: 7-day rabeprazole-based treatment (rabeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: 10-day rabeprazole-based treatment (rabeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Number of subjects: 803

Group type: COMPARATOR
Intervention: 10-day omeprazole-based treatment (omeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Number of subjects: 803
Study: 10408450

Group type: EXPERIMENTAL
Intervention: Hydrogel IOLs
Number of subjects: 90

Group type: COMPARATOR
Intervention: Polymethyl methacrylate IOLs
Number of subjects: 90

Group type: COMPARATOR
Intervention: Silicone IOLs
Number of subjects: 90
Study: 7747846

Group type: EXPERIMENTAL
Intervention: Vital capacity breath
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tidal breathing
Number of subjects: 35
Study: 2286005

Group type: EXPERIMENTAL
Intervention: Sulfadoxine 25 mg/kg + Pyrimethamine 1.25 mg/kg as a single dose (S + P)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Amodiaquine 10 + 10 + 5 mg/kg over three days with Sulfadoxine + Pyrimethamine on the third day (A + S + P)
Number of subjects: 69
Study: 7015798

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg once a day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Methyldopa (250 mg thrice a day)
Number of subjects: 48
Study: 31204680

Group type: EXPERIMENTAL
Intervention: Hysteroscopy before in-vitro fertilisation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 27930383

Group type: EXPERIMENTAL
Intervention: E-OJ-01 (400 mg for 56 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 26361063

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6505
Study: 24057202

Group type: COMPARATOR
Intervention: 0 % (FBP)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 10 % SAFIRE
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 20 % SAFIRE
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 30 % SAFIRE
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 40 % SAFIRE
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 50 % SAFIRE
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 10 % to 50 % SAFIRE
Number of subjects: 70
Study: 21860289

Group type: EXPERIMENTAL
Intervention: Mifepristone followed by misoprostol
Number of subjects: 260

Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 260
Study: 19794330

Group type: EXPERIMENTAL
Intervention: Haloperidol or Risperidone
Number of subjects: 70

Group type: COMPARATOR
Intervention: Atypical antipsychotics
Number of subjects: 70
Study: 17952657

Group type: EXPERIMENTAL
Intervention: Cannabinoids (specifically Sativex®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral administration of cannabinoids
Number of subjects: 0
Study: 15266762

Group type: EXPERIMENTAL
Intervention: Assisted hatching
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control (no assisted hatching)
Number of subjects: 207
Study: 11531898

Group type: EXPERIMENTAL
Intervention: Migraine diagnosis based on IHS criteria
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Alternative criteria for migraine (including attacks < 4 h and > 72 h)
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Physician diagnosis of migraine
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Mean attack frequency
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Mean attack duration
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Strict IHS criteria for migraine
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Alternative criteria for migraine
Number of subjects: 1668
Study: 9753208

Group type: EXPERIMENTAL
Intervention: Sang‐35
Number of subjects: 36

Group type: COMPARATOR
Intervention: Neoral
Number of subjects: 36
Study: 7924177

Group type: EXPERIMENTAL
Intervention: L-carnitine (2 gm per day for 22 weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Antihypertensive drugs only (Control for subgroup A1)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: L-carnitine (2 gm per day for 10 weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Antihypertensive drugs only (Control for subgroup A2)
Number of subjects: 37
Study: 29205608

Group type: EXPERIMENTAL
Intervention: In-utero aspiration (IUA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 61
Study: 26793952

Group type: EXPERIMENTAL
Intervention: Manual thrombus aspiration
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control (no thrombus aspiration)
Number of subjects: 152
Study: 24050787

Group type: EXPERIMENTAL
Intervention: Free school fruit arrangement (receiving one free fruit or vegetable per day)
Number of subjects: 1423

Group type: COMPARATOR
Intervention: No school fruit arrangement
Number of subjects: 1423
Study: 22538532

Group type: EXPERIMENTAL
Intervention: Aspirin 500 mg/d
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 20826169

Group type: EXPERIMENTAL
Intervention: Protein-rich supplements (n=12)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (isocaloric combination of carbohydrate and fat supplements, n=4)
Number of subjects: 16
Study: 18229988

Group type: EXPERIMENTAL
Intervention: QPR training
Number of subjects: 249
Study: 16823511

Group type: EXPERIMENTAL
Intervention: DPPE (tesmilifene) plus doxorubicin (DOX)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Doxorubicin (DOX) alone
Number of subjects: 271
Study: 15055026

Group type: EXPERIMENTAL
Intervention: Surgisis ES mesh
Number of subjects: 20

Group type: COMPARATOR
Intervention: Polypropylene mesh
Number of subjects: 20
Study: 11049908

Group type: EXPERIMENTAL
Intervention: Epinephrine-15 group (3 mL of 1.5% lidocaine containing 15 microg of epinephrine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epinephrine-10 group (2 mL of 1.5% lidocaine containing 10 microg of epinephrine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epinephrine-5 group (1 mL of 1.5% lidocaine containing 5 microg of epinephrine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline group (3 mL of normal saline IV)
Number of subjects: 80
Study: 8922195

Group type: EXPERIMENTAL
Intervention: Vinorelbine (VRB) at a dose of 25 mg/m2 weekly
Number of subjects: 204

Group type: COMPARATOR
Intervention: Vindesine (VDS) at a dose of 3 mg/m2 weekly
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Vinorelbine (VRB) followed by VDS + cisplatin (P)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Vindesine (VDS) followed by VRB + cisplatin (P)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Vinorelbine (VRB)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Vindesine (VDS)
Number of subjects: 204
Study: 1395657

Group type: EXPERIMENTAL
Intervention: Jejunal tube feeding
Number of subjects: 38

Group type: COMPARATOR
Intervention: Gastric tube feeding
Number of subjects: 38
Study: 2859900

Group type: COMPARATOR
Intervention: Almitrine (3 mg X kg‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Almitrine (1.5 mg X kg‐1 X day‐1) for four weeks
Number of subjects: 40
Study: 31555389

Group type: EXPERIMENTAL
Intervention: Montelukast (LTRA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD)
Number of subjects: 0
Study: 30091061

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 27530618

Group type: EXPERIMENTAL
Intervention: Essential information checklist
Number of subjects: 631

Group type: COMPARATOR
Intervention: Unstructured counselling
Number of subjects: 631
Study: 24894625

Group type: EXPERIMENTAL
Intervention: NicVAX
Number of subjects: 558

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Top 30% antibody responders with NicVAX
Number of subjects: 558

Group type: COMPARATOR
Intervention: Top 30% antibody responders with Placebo
Number of subjects: 558
Study: 22722614

Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: TENS vs Exercise
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: TENS vs Acetaminophen
Number of subjects: 79
Study: 20376002

Group type: EXPERIMENTAL
Intervention: Almorexant (doses of 400 mg and above)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Zolpidem (10 mg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Almorexant (500 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 18990679

Group type: EXPERIMENTAL
Intervention: Anterior mandibular repositioning splints
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (untreated adults)
Number of subjects: 34
Study: 15663704

Group type: EXPERIMENTAL
Intervention: Patient education intervention
Number of subjects: 7

Group type: COMPARATOR
Intervention: Local control practices
Number of subjects: 7

Group type: COMPARATOR
Intervention: Distant control practices
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intervention practices
Number of subjects: 7
Study: 12190961

Group type: EXPERIMENTAL
Intervention: Micronised oestradiol (E2) 2 mg daily (n = 16)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined HRT (2 mg E2 daily with trimegestone 0.5 mg daily or dydrogesterone 10 mg daily) (n = 28)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 60
Study: 10208189

Group type: EXPERIMENTAL
Intervention: Combination therapy (albuterol 10 mg/h plus ipratropium bromide 1.0 mg/h)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Albuterol alone (control)
Number of subjects: 67
Study: 8544658

Group type: EXPERIMENTAL
Intervention: AIDS patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study: 2132343

Group type: EXPERIMENTAL
Intervention: Dopamine (D)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dopamine-nitroprusside (DN)
Number of subjects: 36
Study: 649240

Group type: EXPERIMENTAL
Intervention: 40 mg of papaverine
Number of subjects: 19

Group type: COMPARATOR
Intervention: 1.0 ml of physiological saline (placebo)
Number of subjects: 19
Study: 31084442

Group type: EXPERIMENTAL
Intervention: Cognitive theory-based intervention (CDT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Care-as-usual (Control)
Number of subjects: 79
Study: 27884664

Group type: EXPERIMENTAL
Intervention: Needle technique
Number of subjects: 110

Group type: COMPARATOR
Intervention: Tray technique
Number of subjects: 110
Study: 25926298

Group type: EXPERIMENTAL
Intervention: Multipoint transcutaneous electrical acupuncture stimulation (TEAS)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sham TEAS
Number of subjects: 92
Study: 24412249

Group type: EXPERIMENTAL
Intervention: Custom foot orthotics with limited chiropractic care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flat insole sham with limited chiropractic care
Number of subjects: 0
Study: 21181706

Group type: EXPERIMENTAL
Intervention: Nanofill composite (Filtek Z350)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nanohybrid composite (Esthet‐X)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Microhybrid composite (Filtek Z250)
Number of subjects: 41
Study: 19129268

Group type: EXPERIMENTAL
Intervention: Lone mothers
Number of subjects: 464

Group type: COMPARATOR
Intervention: Married/partnered mothers
Number of subjects: 464
Study: 17448700

Group type: EXPERIMENTAL
Intervention: diacerein 100mg/day
Number of subjects: 171

Group type: COMPARATOR
Intervention: piroxicam 20mg/day
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: diacerein
Number of subjects: 171

Group type: COMPARATOR
Intervention: piroxicam
Number of subjects: 171
Study: 15666492

Group type: EXPERIMENTAL
Intervention: Irbesartan (300 mg/die)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Chlortalidone (50 mg/die)
Number of subjects: 2
Study: 12495257

Group type: EXPERIMENTAL
Intervention: Iron-folate tablets (200 mg FeSO4 and 250 microg folic acid) + 5 mg riboflavin (group IFR)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Iron-folate tablets (200 mg FeSO4 and 250 microg folic acid) + 2.75 mg retinyl palmitate (equal to 5000 IU vitamin A) (group IFA)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Iron-folate tablets (200 mg FeSO4 and 250 microg folic acid) + 5 mg riboflavin + 2.75 mg retinyl palmitate (group IFRA)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Iron-folate tablets (200 mg FeSO4 and 250 microg folic acid) + 5 mg glucose (group IF)
Number of subjects: 103
Study: 10333395

Group type: EXPERIMENTAL
Intervention: Intra-amniotic infection
Number of subjects: 37

Group type: COMPARATOR
Intervention: No intra-amniotic infection
Number of subjects: 37
Study: 8595510

Group type: EXPERIMENTAL
Intervention: Combination therapy with 3TC (300 mg b.i.d.) plus AZT (200 mg t.i.d.) for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: AZT monotherapy (200 mg t.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with 3TC (300 mg b.i.d.) plus AZT (200 mg t.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with 3TC (150 mg b.i.d.) plus AZT (200 mg t.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AZT monotherapy (200 mg t.i.d. plus placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with AZT and 3TC
Number of subjects: 0
Study: 2651031

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Multiple injection technique (MIT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional treatment (CT)
Number of subjects: 10
Study: 345888

Group type: EXPERIMENTAL
Intervention: Environmental control (rigidly controlled, relatively fume‐ and particle‐free environment)
Number of subjects: 12
Study: 28847751

Group type: EXPERIMENTAL
Intervention: GED‐0301 (160 mg/day) for 4 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: GED‐0301 (160 mg/day) for 8 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: GED‐0301 (160 mg/day) for 12 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Endoscopic improvement at week 12
Number of subjects: 63
Study: 27306435

Group type: EXPERIMENTAL
Intervention: Sedentary time (SB)
Number of subjects: 4169

Group type: EXPERIMENTAL
Intervention: Light-intensity physical activity (LPA)
Number of subjects: 4169

Group type: EXPERIMENTAL
Intervention: Moderate- to vigorous-intensity physical activity (MVPA)
Number of subjects: 4169

Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 4169
Study: 24769270

Group type: EXPERIMENTAL
Intervention: Home telemonitoring
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 204
Study: 22042908

Group type: EXPERIMENTAL
Intervention: Hip protectors
Number of subjects: 116
Study: 20923694

Group type: EXPERIMENTAL
Intervention: Right prefrontal HF‐rTMS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left prefrontal HF‐rTMS
Number of subjects: 0
Study: 18404609

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 156

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 156
Study: 16162741

Group type: EXPERIMENTAL
Intervention: Mitomycin-ifosfamide-cisplatin followed by surgery
Number of subjects: 167

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 167